Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The management presentation is scheduled for Thursday, April 20th, at 1:30 p.m. ET (10:30 a.m. PT). Interested parties can access the live and archived webcast through the company's investor relations website.
Absci specializes in combining AI with scalable wet lab technologies to enhance drug development, aiming to accelerate time to clinic and improve success rates. Its Integrated Drug Creation™ platform allows rapid screening and validation of drug candidates. The company is headquartered in Vancouver, WA, with additional facilities in New York and Zug, Switzerland.
Absci Corporation (Nasdaq: ABSI) has partnered with M2GEN to leverage its generative AI platform and M2GEN's clinicogenomic database to accelerate the creation of new cancer treatments. This collaboration aims to streamline the drug discovery process, utilizing M2GEN's ORIEN AVATAR® data to identify specific antigens for immunotherapies. Absci's Integrated Drug Creation™ platform can reduce the time from AI-designed antibodies to lab-validated candidates to as little as six weeks. With over 360,000 patients enrolled in M2GEN's Total Cancer Care® protocol, this partnership seeks to revolutionize personalized medicine in oncology.
Absci Corporation (Nasdaq: ABSI) reported transformative results for 2022, achieving industry breakthroughs in drug development using generative AI. Key highlights include:
- Revenue rose to $5.7 million from $4.8 million year-over-year.
- R&D expenses increased to $58.9 million, reflecting enhanced platform capabilities.
- Net loss reduced to $104.9 million from $101.0 million.
- Cash reserves as of December 31, 2022, totaled $164.4 million.
Looking forward, Absci expects to add at least ten new active programs in 2023, enhancing its partnerships and cash flow.
Absci Corporation (Nasdaq: ABSI) announced its participation in the B. Riley Securities' Life Sciences Tools Conference on April 6, 2023. The event focuses on integrating AI and proteomics into drug discovery. Absci’s management will engage in a panel discussion at 7:30 a.m. PT and a fireside chat at 12:30 p.m. PT. Interested parties can access the live webcast by registering through the conference's website. Absci specializes in generative AI drug creation, aiming to expedite the development of biologics and enhance therapeutic benefits through its Integrated Drug Creation™ platform.
Absci Corporation (Nasdaq: ABSI) recently announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum scheduled for March 21, 2023, at 3:00 p.m. Eastern Time. This virtual event will feature a fireside chat with Absci management, providing insights into the company's innovative generative AI drug creation technologies.
Absci leverages AI alongside advanced wet lab methods to accelerate drug development, enhancing the probability of success by optimizing various drug characteristics. Interested parties can stream the event live via the company's investor relations website.